Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Return on Capital Employed (2021 - 2025)

TScan Therapeutics (TCRX) has disclosed Return on Capital Employed for 5 consecutive years, with 0.57% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 15.0% to 0.57% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.57%, a 15.0% decrease, with the full-year FY2025 number at 0.48%, down 1.0% from a year prior.
  • Return on Capital Employed was 0.57% for Q4 2025 at TScan Therapeutics, down from 0.43% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.28% in Q4 2021 to a low of 0.57% in Q4 2025.
  • A 5-year average of 0.4% and a median of 0.41% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: increased 10bps in 2023, then decreased -15bps in 2025.
  • TScan Therapeutics' Return on Capital Employed stood at 0.28% in 2021, then plummeted by -45bps to 0.4% in 2022, then grew by 8bps to 0.37% in 2023, then fell by -12bps to 0.42% in 2024, then plummeted by -37bps to 0.57% in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Return on Capital Employed are 0.57% (Q4 2025), 0.43% (Q1 2025), and 0.42% (Q4 2024).